Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Rodriguez-Moreno, J. F.
de Velasco, G.
Alvarez-Fernandez, C.
Collado, R.
Fernandez-Rodriguez, R.
Vazquez Estevez, S.
Virizuela Echaburu, J. A.
Gajate Borau, P.
Font, A.
Lainez, N.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
